Filing Flows › Relay Therapeutics (RLAY) › Stock forecast & fair value
Relay Therapeutics (RLAY) stock forecast and price target
Relay Therapeutics (RLAY) trades at $18.60. 12 analysts' median price target is $29.00 (+56%), from $25.00 to $32.00.
Relay Therapeutics' latest quarter
Relay Therapeutics, Q2 2026: revenue $350K (-48% year over year), net loss $83.7M, operating cash flow −$54.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for RLAY stock?
The median of 12 analysts' 12-month targets is $29.00, +56% from $18.60; the range is $25.00 to $32.00. The average rating is strong buy.
Does Relay Therapeutics usually beat earnings estimates?
It beat the consensus EPS estimate in 40% of the quarters on record.
Is RLAY stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.